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Summary 27 
 The complement factor H-related proteins (FHRs) are strongly associated with 28 
different diseases involving complement dysregulation, which suggests a major role for these 29 
proteins regulating complement activation. Because the FHRs are evolutionarily and 30 
structurally related with the complement inhibitor factor H (FH), the initial assumption was 31 
that the FHRs are also negative complement regulators. Despite weak complement inhibiting 32 
activities were originally reported for these molecules, recent developments indicate that the 33 
FHRs may rather enhance complement activation and are providing novel insights into their 34 
role in health and disease. FHRs are now envisioned as a complex set of surface recognition 35 
molecules that, by competing with FH, provide improved discrimination of the self and non-36 
self/foreign surfaces where complement activation should appropriately take place.  37 
38 
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Introduction 39 
 The complement system is an essential part of the innate immunity, with decisive roles in 40 
the protection against infections, but also participating in the modulation of inflammation, the 41 
disposal of immune complexes, cellular waste and apoptotic/necrotic cells, or in the activation 42 
and regulation of innate and adaptive immune cells [1]. Preserving the physiological balance 43 
between complement activation and inhibition is absolutely required to maintain homeostasis 44 
by targeting appropriate sites for activation but also avoiding at the same time bystander 45 
damage to host tissues. This is ensured by proper target recognition mechanisms that initiate 46 
and amplify complement activation only when it is necessary, by the built-in specificity and 47 
limited activity of the enzymatic complexes (C3/C5 convertases) of the system, and by an 48 
array of receptors and regulatory molecules that control the activation cascade at different 49 
steps (BOX 1). Imbalance between activation and inhibition due to excessive activation or 50 
improper regulation has pathological consequences [2-5]. Here we will review recent 51 
developments that provide novel insights into how complement is regulated on self and non-52 
self biological surfaces and the implications that this understanding have in health and 53 
disease. 54 
 55 
The FH/FHR protein family 56 
Six genes positioned in tandem arrangement encode the members of the FH/FHR protein 57 
family. This family includes FH and FHL-1, both derived from CFH via alternative splicing, 58 
and the FHR-1, -2, -3, -4 and -5 proteins coded by the CFHR1-5 genes. FHR-1 has two allelic 59 
variants FHR-1*A and FHR-1*B, and FHR-4 two isoforms FHR-4A and FHR-4B (Figure 1). 60 
All these proteins are composed of repetitive units of ~60 aa named short consensus repeats 61 
(SCRs) (GLOSSARY), arranged in a continuous fashion. The CFHR1-5 genes originated 62 
from the CFH gene by tandem duplication events [6] (Figure 1A). The C-terminal region 63 
(SCRs 18-20) and SCRs 6-7 of FH, harbouring the major surface recognition sites of FH, are 64 
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retained with different degrees of conservation in all FHRs, explaining their capacity to 65 
interact with most of the FH ligands (Table 1) [7-9]. However, none of the FHRs contain 66 
regions homologous to FH SCRs 1-4, which questions conservation of the FH complement 67 
regulatory activities in the FHRs (Figure 1B, 1C). 68 
A remarkable characteristic of FHR-1, FHR-2 and FHR-5 is that the two N-terminal SCRs, 69 
which are almost identical in these FHRs (Figure 1C), include a dimerization domain [10]. 70 
This determines that these FHRs, in contrast to FH, always circulate in plasma as dimers or 71 
tetramers (Figure 1D) [10, 11]. This structural organization has major functional implications. 72 
By assembling into homo- and hetero-oligomeric complexes, FHR-1, FHR-2 and FHR-5 73 
increase their avidity for their ligands (C3b, iC3b, C3dg and carbohydrates). In addition, 74 
because the FHR composition of the different oligomers influences the carbohydrate binding 75 
characteristics for each of these FHR complexes, a combinatorial repertoire of different FHRs 76 
likely provide finer identification of opsonised surfaces with different carbohydrate 77 
compositions and different densities and rates of deposition of C3 fragments. 78 
 79 
FHRs and Disease 80 
Genetic variations in the FHRs are associated with different diseases, including C3 81 
Glomerulopathies (C3G), atypical Hemolytic Uremic Syndrome (aHUS), IgA Nephropathy 82 
(IgAN), Systemic Lupus Erythematosus (SLE) and Age-related Macular Degeneration 83 
(AMD) [12-24]. Among them, variations involving CFHR1-5 genomic rearrangements (Table 84 
2) are most remarkable and informative. These rearrangements are not unusual because the 85 
region contains large genomic duplications (Figure 1A), which makes it highly prone to 86 
genomic rearrangements through gene conversion and non-allelic homologous recombination 87 
[6]. 88 
Rearrangements resulting in the generation of hybrid genes between CFH and CFHR1 or 89 
CFHR3 strongly associate with aHUS, a rare kidney disease characterized by impaired 90 
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regulation of complement activation on endothelial surfaces leading to thrombotic 91 
microangiopathy. Notably, FH proteins in which the last C-terminal SCR20 has been replaced 92 
by the C-terminal SCR5 of FHR-1 or by the whole FHR-3, namely FH::FHR-1 and FH::FHR-93 
3 hybrids, are unable to regulate complement properly on endothelial surfaces [25-28]. 94 
Similarly, the FHR-1::FH hybrid protein in which the C-terminal SCR5 of FHR-1 has been 95 
replaced by SCR20 of FH also impairs complement regulation by competing binding of FH 96 
itself to the endothelium [29]. As a whole, data generated from the study of the 97 
CFH::CFHR1/CFHR3 hybrid genes  [25-27, 29-31] illustrate the critical role that the C-98 
terminal region of FH plays in the protection of host surfaces from complement damage and 99 
that this region in FH cannot be replaced by the C-terminal region of FHR-1 or FHR-3; FH 100 
and FHR-1/FHR-3 have different binding specificities. Notably, the observation that the FHR-101 
1::FH hybrid protein impairs complement regulation also indicates that FHR-1 lacks 102 
appropriate complement regulatory activity to substitute FH [29].  103 
A second type of rearrangement in the CFH/CFHR1-5 region is the deletion of the CFHR3 104 
and CFHR1 genes. This is a common polymorphism in humans with allelic frequencies 105 
ranging from 0 to 0.55 in different populations [32], which originated from a single non-106 
allelic homologous recombination event involving a duplicated region downstream of CFH 107 
and CFHR1 [33]. Remarkably, the CFHR3-CFHR1 deletion is strongly associated with lower 108 
risk of AMD [17] and IgAN [16], two prevalent conditions affecting the retina and the kidney, 109 
respectively. In contrast, the CFHR3-CFHR1 deletion is a risk factor for SLE and 110 
autoimmune aHUS [24, 32, 34].  111 
Finally, there is a set of genomic rearrangements resulting in the duplication of the 112 
dimerization domain of FHR-1, FHR-2 and FHR-5, which are specifically associated with 113 
C3G, a heterogeneous group of rare glomerulopathies leading to renal failure characterized by 114 
massive deposition of C3 derivatives along the glomerular basement membrane (GBM) [11, 115 
12, 14, 15, 35, 36]. This duplication of the dimerization domain causes abnormal 116 
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multimerization of FHR-1, FHR-2 and FHR-5, which increases avidity for their ligands and 117 
enhances competition with FH [10, 11]. It is postulated that these gain-of-function mutant 118 
FHR-1, FHR-2 and FHR-5 proteins are pathogenic because they over-compete FH binding to 119 
host surfaces and impair complement regulation.  120 
As described, the association of the CFH/CFHRs rearrangements with disease suggests 121 
that FHRs originated to modulate complement activation by competing the binding of FH to 122 
surfaces and that this competition can be beneficial or detrimental depending on the 123 
surfaces/circumstances.  124 
 125 
The evolving understanding of the role of the FHR proteins 126 
Because of their homology with FH, complement regulatory roles were originally 127 
postulated for the FHRs [37]. The initial studies, however, could not demonstrate FH-like 128 
activity for these proteins [38]. Subsequent studies showed weak cofactor activities of FHR-3, 129 
FHR-4 and FHR-5 [39, 40] and synergistic activity with FH, namely, enhancement of the 130 
cofactor activity of FH in the case of FHR-3 and FHR-4 [39]. Notably, though, high and now 131 
known to be non-physiological concentrations of the FHR-3 and FHR-4 proteins were 132 
required for these activities. FHR-5 was also reported to inhibit the alternative pathway (AP) 133 
C3 convertase [40] and more recently strong cofactor activity was shown for FHR-3 [41], 134 
although this again required a concentration above the likely (yet precisely undefined) plasma 135 
concentration of FHR-3 [42]. One study reported a complement inhibiting function for FHR-2 136 
[43] and another showed that FHR-1, instead of having FH-like regulatory activity, inhibits 137 
the lytic pathway [44], although others demonstrated that FHR-1 could not significantly 138 
influence and inhibit complement-mediated lysis of sheep erythrocytes [29, 45].  139 
The ability of recombinant FHR-1 and FHR-5 proteins or native FHR-1, FHR-2 and FHR-140 
5 oligomers to regulate C3b and the AP has now been more extensively analysed using 141 
hemolytic assays and surface plasmon resonance. These analyses demonstrated that these 142 
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FHRs bind to C3b, iC3b, and C3dg, but provided no evidence of cofactor activity for the FI-143 
mediated proteolysis of C3b or AP C3 convertase decay accelerating activities [10, 11]. These 144 
studies also failed to detect any significant interaction of FHR-1 with C5 [10], indicating that 145 
FHR-1, FHR-2 and FHR-5 have no intrinsic C3 or C5 regulatory activity at physiological 146 
concentrations. On the other hand, these experiments showed that the FHR-1, -2 and -5 147 
proteins, through their ability to compete with FH for binding to C3b, actually prevent FH-148 
mediated complement regulation. This interference with the FH regulatory activities is 149 
apparently facilitated by their oligomerization, which increases avidity for their ligands, and is 150 
significantly enhanced by the rare C3G-associated mutations that results in abnormal 151 
multimerization of the FHR-1, FHR-2 and FHR-5 proteins [10, 11]. Importantly, it has been 152 
reported that FHR-3 and FHR-4 are also able to compete for FH ligands and therefore have 153 
the potential to interfere with FH regulation [41, 46].  154 
In addition to playing important roles in controlling FH activities on self, FH and some of 155 
the FHRs have also been found to interact with several microbes and microbial proteins. 156 
However, only few studies have addressed the functional consequences of the interaction of 157 
the FHR proteins with pathogens. These studies showed that none of the bound FHRs (FHR-158 
1, FHR-2 and FHR-5) conferred protection from complement activation and deposition of 159 
C3b and C5b-9, whereas binding of FH could reduce or completely block C3b and C5b-9 160 
deposition and lysis [47]. This suggests that FH but not the FHRs protect the microbes from 161 
opsonophagocytosis and/or complement-mediated damage when bound on the microbial 162 
surface. Strikingly, the FH domains that are well conserved among the FHRs are those that 163 
mediate the binding of FH to most known FH-binding pathogens and microbial proteins 164 
(Figure 2), raising the possibility that the FHRs have evolved as decoys to reduce the amount 165 
of FH bound by the pathogens and, consequently, potentiate their elimination mediated by the 166 
host complement system. 167 
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Very recent experiments with the major human pathogen Neisseria meningitidis provide 168 
strong support to these ideas [46]. N. meningitidis recruits FH via fHbp, a surface lipoprotein 169 
that mimics host carbohydrates and binds FH with high affinity [48]. In their report, Caesar et 170 
al. elegantly show that FHR-3 binds fHbp with similar affinities that FH and that FHR-3 171 
competes with FH on the bacterial surface, influencing N. meningitidis survival in serum 172 
sensitivity assays. These findings may explain the earlier observation that individuals carrying 173 
a particular extended CFH-CFHR3-CFHR1 haplotype present significant protection to N. 174 
meningitdtis infections [49]. Notably, this haplotype (H3 haplotype), which is also an 175 
important risk factor for aHUS, determines significantly lower levels of FH and includes 176 
polymorphisms in potential CFHR3 regulatory regions that may also affect FHR-3 expression 177 
in plasma (Bernabeu-Herrero et al., Submitted).  178 
Some FHRs seem to have acquired functions that enhance complement activation on the 179 
surface of pathogens. For example, FHR-4 binds preferentially the native, pentameric form of 180 
CRP (pCRP) and can thus allow complement activation [50, 51], whereas FH binds mainly 181 
the modified, monomeric form of CRP (mCRP) at lower concentrations [51-53]. Similarly, 182 
both FHR-4 and FH bind to C3b, but only FH promotes inactivation of C3b efficiently; FHR-183 
4 rather enhances complement activation by allowing AP convertase formation on FHR-4-184 
bound C3b [54]. This mechanism may result in enhanced opsonization of dying cells or some 185 
pathogens in the presence of FHR-4 [55, 56]. 186 
Taken together, all of these recent data suggest that the FHRs modulate complement 187 
activation by competing with FH for binding to its ligands. In contrast to the binding of FH to 188 
surfaces, which prevents further C3b generation and deposition (negative regulation), the 189 
binding of the FHRs enables C3b amplification to proceed unhindered. This competition with 190 
FH would be influenced by the concentration and composition of the FHRs relative to FH at 191 
the site of complement activation, the density and relative deposition of C3b, iC3b and C3dg, 192 
the carbohydrate and polyanion composition and the presence of additional ligands on the 193 
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complement-activating surface. Understanding all these factors will help to understand the 194 
association of the FHRs with disease. 195 
 196 
Competition between FH/FHL-1 and FHRs on host and altered host surfaces or 197 
molecules. 198 
The main function of FH/FHL-1 is to control the AP amplification loop and to prevent 199 
tissue damage by accidental complement activation on self-surfaces. Basically, the role of FH 200 
is to maintain the density of C3b molecules on host surfaces below a critical threshold, 201 
because if this threshold is exceeded, C3b amplification runs off without control and tissue 202 
damage occurs. A first consideration regarding the postulated competitor role of the FHRs is 203 
what prevents them from inhibiting the function of FH protecting the normal host cell 204 
surfaces and causing disease. A likely answer to this question is that despite the very high 205 
conservation of the FH surface recognition domains in some of the FHRs (Figure 1), 206 
competition on normal host tissues is very limited. This affirmation is supported by 207 
observations in aHUS patients indicating that exchanging the C-terminal regions between FH 208 
and FHR-1 has identical pathogenic consequences to that of the disease-associated FH 209 
mutations that disrupt the C-terminal functionalities (Figure 3A). Therefore, despite there are 210 
only two amino acid differences (S1191L, V1197A) between the C-terminal regions of FH 211 
and FHR-1, these differences are sufficient to alter sialic acid recognition [57], conferring 212 
distinct surface binding specificity to FH and FHR-1 and eliminating the risk of an 213 
undesirable competition between them for host tissues. The possibility that the FH/FHR 214 
competition affects mainly a specific subset of surfaces, which does not include normal host 215 
surfaces, may help to understand the association of the FHRs with pathology. Our proposal is, 216 
therefore, that the FHRs originated through evolution to prevent binding of FH to certain 217 
pathogens (Figure 3B) and that they also compete binding of FH to altered host surfaces 218 
(Figure 3C), perhaps because these altered host surfaces include molecules that resemble 219 
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those present on the surface of pathogens. This proposal assumes that there must be 220 
complement activation and C3 deposition on these surfaces (spontaneous, following a trigger, 221 
or both) that would be accelerated in the presence of these FHR proteins. The presence of the 222 
activated C3 fragments iC3b and C3dg, which are better ligands for some FHRs than for FH 223 
[10, 11], may be crucial to sustain a competition between FH and the FHRs at these surfaces. 224 
Additional poorly characterized “injury-associated” changes in host surfaces may favour this 225 
competition [58].  226 
In this setting, the relative amounts of FH and FHRs, established by their levels of 227 
expression or activity, appear critical to modulate complement regulation and to determine 228 
susceptibility to complement-mediated injury. Plasma levels of FH vary widely (116–562 229 
μg/ml) in humans as the result of the combined effect of genetic and environmental factors. 230 
Notably, 63% of the variation in plasma levels of FH is determined genetically by 231 
polymorphisms likely linked to the CFH gene in 1q32 [59]. Strong linkage dysequilibrium 232 
limits the genetic variability in that genetic region to a few CFH-CFHR3-CFHR1 extended 233 
haplotypes [2, 17]. Interestingly, two of these haplotypes that have been strongly associated 234 
with various diseases determine significantly different plasma levels of FH and FHRs. 235 
Haplotype H3 determines significantly lower levels of FH in plasma and may also affect 236 
FHR-3 levels in plasma (Bernabeu-Herrero et al., submitted). This could imply an increased 237 
competition between FH and FHR-3 and may explain the association of this haplotype with 238 
protection to meningococcal disease [59]. Haplotype H4 carries the CFHR3-CFHR1 deletion 239 
and also determines increased levels of FH [60], a combination that, enhancing FH regulation 240 
on surfaces, could explain the association of this haplotype with protection against AMD and 241 
IgAN [2, 17]. 242 
Despite these genetically determined population variations, FH serum levels are not 243 
actively regulated individually [59], which may not be the case for FHRs. One report suggests 244 
that the concentrations of FHRs increase upon infection [61] and there is evidence that FHRs 245 
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levels may also change in other situations (our own data) [62, 63]. Changes in FHRs levels 246 
may explain the episodic nature of some diseases associated with complement dysregulation 247 
in which relapses often associate with infection (i.e., C3G, IgAN). The possibility that FHR 248 
levels may be influenced by physiological and pathological conditions warrant further studies 249 
since it would be predicted that a local increase in the concentration of the FHRs would, 250 
through enhanced FH competition, enable (rapid) enhancement of complement activation.  251 
The FH/FHRs balance may also be altered in situations in which the FHRs are mutated and 252 
acquire gain-of-function activities. Hybrid and mutant FHR-1, FHR-2 or FHR-5 proteins 253 
containing a duplicated dimerization domain are good examples of this situation [10, 11, 14]. 254 
Similarly, the association with C3G of novel CFHR3::CFHR1 and CFHR5::CFHR2 hybrid 255 
genes may be explained by an altered FH/FHR balance [64]. These hybrid genes express the 256 
hybrid protein on top of the FHRs produced by the normal copies of CFHR1 and CFHR3, 257 
which result in increased levels of these FHRs to compete FH. 258 
The identification of the specific surfaces that sustain the FH/FHR competition in these 259 
pathologies is, however, challenging. The GBM and the Bruch’s membrane (BM) are good 260 
candidate surfaces for competition between FH/FHL-1 and FHRs. It has been shown that FH, 261 
FHL-1, FHR-1 and FHR-5 bind to extracellular matrix components (ECM), the major 262 
constituent of the GBM and the BM, and that FHR-5 inhibits the surface-associated cofactor 263 
activity of FH by competing its binding to the ECM [65-67]. This competition may increase 264 
by the presence of microbial ligands or other physiological or pathological substances 265 
deposited together with C3 activated fragments along the GBM or the BM. 266 
In addition, there are additional molecules on apoptotic cells, retinal deposits and other 267 
structures that can sustain this FH/FHRs competition. One of such ligands is malondialdehyde 268 
(MDA) epitopes that originate from peroxidation of membrane lipids due to oxidative stress 269 
[68]. It is thought that MDA epitopes are responsible for the recruitment of FH to the surface 270 
of apoptotic cells, where FH neutralizes their proinflammatory properties and halts 271 
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complement activation [69]. In AMD, a common eye condition among elderly people this 272 
situation may be particularly relevant as in the retina dying cells are continuously generated 273 
and need to be efficiently removed. FH binds MDA epitopes through SCRs 6-7 and SCRs 19-274 
20, which may explain the association of both, the 402His polymorphism in SCR7 with 275 
increased risk and the CFHR3-CFHR1 deletion with strong protection to AMD [17, 70-73]. 276 
Accordingly, the FH risk variant 402His was shown to present decreased binding to MDA 277 
compared to the 402Tyr variant and evidence was provided suggesting that FHR-1 could 278 
compete the binding of FH to MDA [69]. 279 
IgA nephropathy (IgAN) is a common form of primary glomerulonephritis characterized 280 
by galactose-deficient IgA1 (Gd-IgA1)-containing immune complexes that deposit in the 281 
glomerular mesangium producing progressive kidney disease [74]. IgAN is also strongly 282 
associated with the CFHR3-CFHR1 deletion [16]. Similarly to AMD, the reported protection 283 
to IgAN conferred by the lack of FHR-3 and FHR-1 may also relate to the generation of 284 
altered host surfaces. Pathogenesis of IgAN is currently modelled as a sequence of multiple 285 
events, one of them being the generation of antiglycan antibodies that recognize GalNAc-286 
containing epitopes on Gd-IgA1 [75]. It is possible that Gd-IgA1-containing immune 287 
complexes deposited in the mesangium may resemble pathogen surfaces where competition 288 
between FH and FHRs may occur. We speculate that this competition would be further 289 
enhanced by the deposition of the C3 activated fragments generated by activation of the lectin 290 
pathway [76]. The advantage of individuals carrying the CFHR3-CFHR1 deletion would be to 291 
have less FHRs to interfere with the regulation by FH of the complement activation induced 292 
by these (Gd-IgA1)-antiglycan immune complexes in the kidney. 293 
Complement also plays an important role in SLE, a severe autoimmune disease 294 
characterized by the presence of autoantibodies that result in tissue injury of multiple organs 295 
[24]. Here, in contrast to AMD and IgAN, the CFHR3-CFHR1 deletion represents an 296 
important predisposition factor, suggesting that in this case decreased FH/FHR competition is 297 
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deleterious.  Two possibilities have been proposed to explain this association; one is based on 298 
the capacity of FHR-1 to inhibit C5 convertase activity and MAC formation, a role of FHR-1 299 
that is currently controversial. The second explanation relates to the possibility that carriers of 300 
the CFHR3-CFHR1 deletion generate autoantibodies against FH, similarly to the situation in 301 
aHUS where these antibodies are associated with the homozygous deficiency of FHR-1 [77]. 302 
The contrasting phenotypic association of SLE with the CFHR3-CFHR1 deletion, opposing 303 
the protective effect observed for IgAN and AMD, may also suggest that some AP activation 304 
could be beneficial in SLE. For example, the CFHR3-CFHR1 deletion may result in less 305 
opsonization and opsonophagocytic removal of autoantigens due to increased complement 306 
regulation by FH on apoptotic cells. In that setting, enhanced levels of autoantigens may 307 
promote production of pathogenic autoantibodies recognizing these targets. 308 
 309 
Conclusions 310 
As a whole, there is little convincing evidence for the existence of physiologically-relevant 311 
complement-inhibitory activities of the FHRs. On the other hand, recent data and critical 312 
evaluation of previous studies suggest a FH antagonistic function for the FHRs, termed 313 
complement de-regulation. Future studies will define the ligands and surface specificity of the 314 
FHRs in more detail and also the conditions under which competition with FH occurs. This 315 
knowledge will advance our understanding of the pathogenic mechanisms of several diseases 316 
associated with complement dysregulation. We do not exclude that FHRs may have functions 317 
independent of the activity of FH, such as the enhancement of complement activation as 318 
showed for FHR-4 and even some complement inhibitory activities. Currently, however, 319 
strong in vitro evidence and data from different diseases suggest a major role of the FHRs as 320 
competitive inhibitors of FH for fine-tuning discrimination of complement activating surfaces. 321 
 322 
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BOX.  Complement activation and its regulation by FH 341 
Pathogens, altered host cells or molecules and certain host ligands released/exposed during 342 
infections and inflammatory processes, such as pentraxins, molecules of the extracellular 343 
matrix and DNA, can activate complement. The classical complement pathway is activated by 344 
immunoglobulins, pentraxins or by the direct binding of C1q to such ligands/surfaces. The 345 
lectin pathway is initiated via target-bound mannose-binding lectin or ficolins. The C3b 346 
fragment generated from C3 through these activation routes feeds into the alternative pathway 347 
(AP), amplifying the classical and lectin pathway-mediated activation. The tick-over 348 
mechanism [78] ensures a low-rate constant activation of C3 in plasma through the AP. 349 
Properdin may also act as an AP initiator [79]. Cleavage of C3 into C3b results in the covalent 350 
binding of C3b to the activating surface. Incorporation of additional C3b molecules to the 351 
surface-bound AP C3-convertases generates the C5-convertases with the capacity to bind and 352 
cleave C5, leading to the initiation of the lytic pathway and the generation of terminal 353 
complement complexes (termed membrane attack complex (MAC) when integrated into 354 
target cell membranes) (Figure). Regulation of complement activation is a necessary and 355 
complex process involving several soluble and membrane-associated proteins (Depicted in 356 
red in the figure).  Among them factor H (FH), the major regulator of the AP, is the 357 
prototypical member. FH is a relatively abundant plasma protein that is essential to maintain 358 
complement homeostasis and to restrict the action of complement to activating surfaces. FH 359 
binds to C3b, accelerates the decay of the AP C3-convertase (C3bBb) and acts as a cofactor 360 
for the factor I (FI)-mediated proteolytic inactivation of C3b. FH regulates complement both 361 
in fluid phase and on cellular surfaces. However, while FH binds and inactivates promptly 362 
C3b in fluid phase, the inactivation of surface-bound C3b by FH is dependent on the chemical 363 
composition of the surface to which C3b is bound. In the presence of polyanions like sialic 364 
acids, glycosaminoglycans or sulphated polysaccharides (heparins), the affinity of FH for 365 
surface-bound C3b increases as a consequence of the simultaneous recognition of both 366 
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polyanionic molecules and bound C3b by the same FH molecule [57, 67, 80, 81]. 367 
Abbreviations for other complement proteins depicted in the figure are C4b-binding protein 368 
(C4bp), membrane cofactor protein (MCP, CD46), decay accelerating factor (DAF, CD55) 369 
and complement receptor type 1 (CR1; CD35).  These proteins restrict complement activation 370 
on self-tissues by either catalyzing proteolytic inactivation of C3b/C4b by FI (MCP, CR1, 371 
C4bp) or accelerating convertase dissociation (DAF, CR1, C4bp). 372 
373 
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Glossary Box 374 
Age-related macular degeneration: a major cause of blindness among the elderly, with 375 
multiple predisposing factors including complement gene variants, and characterized by 376 
the accumulation of waste material along the Bruch’s membrane in the retina. 377 
Atypical hemolytic uremic syndrome: a form of thrombotic microangiopathy characterized 378 
by hemolytic anemia, low platelet count  and acute renal failure, with predisposing 379 
complement gene variants or autoantibodies to factor H. 380 
C3 glomerulopathy: various forms of glomerulonephritis characterized by involvement of 381 
the alternative complement pathway and C3 deposition in the glomeruli. 382 
Cofactor activity: the ability of factor H and some other complement regulators to assist the 383 
serine protease factor I in the enzymatic degradation of the central complement 384 
fragment C3b. 385 
Complement de-regulation: the ability of the factor H-related proteins to competitively 386 
inhibit the complement regulator factor H. 387 
Decay accelerating activity: the capacity of factor H and a few other complement regulators 388 
(decay accelerating factor, complement receptor type 1) to facilitate the disassembly of 389 
the C3 convertase enzyme (C3bBb). 390 
Haplotype: A set of DNA variations (i. e., mutations, single nucleotide polymorphisms, copy 391 
number variations) found on the same chromosome and that tend to be inherited 392 
together. 393 
IgA nephropathy: a form of glomerulonephritis characterized by IgA-containing immune 394 
complexes. 395 
MAC: membrane attack complex, a pore formed by complement proteins C5b, C6, C7, C8 396 
and C9 in the cell membrane of target cells. 397 
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MDA epitopes: malondialdehyde epitopes that originate from peroxidation of membrane 398 
lipids due to oxidative stress and that modify primary amino groups in proteins and 399 
lipids . 400 
SCR domain: short consensus repeat or Sushi domain, also known as complement control 401 
protein (CCP) domain, a domain characteristic to many complement regulatory and 402 
other proteins. 403 
SLE: systemic lupus erythematosus, a systemic autoimmune disease characterized by anti-404 
DNA and other autoantibodies. 405 
Table 1. Known host ligands of the human FHR proteins 406 
 407 
Protein Ligand Associated function Reference 
FHR-1 
C3b, C3d Competition with FH (no cofactor / decay accelerating activity) [10, 11, 38, 44] 
Heparin Unknown [44] 
PTX3 Unknown [67] 
C5 Terminal pathway inhibition (Questioned by others) [10, 44, 82] 
Lipoproteins (HDL) Unknown [83] 
CR3 Cellular adhesion [55] 
    
FHR-2 
C3b, C3d Inhibition of C3 convertase (no cofactor and decay accelerating activity). Terminal pathway inhibition [43] 
Heparin Unknown [43] 
Lipoproteins (HDL) Unknown [83] 
    
FHR-3 
C3b, C3d Enhancement of FH cofactor activity [39] 
C3b Cofactor activity [41] 
Heparin Unknown [39] 
    
FHR-4A 
FHR-4B 
C3b, C3d Enhancement of FH cofactor activity [39, 54] 
C3b Enhancement of AP activation [54] 
CRP Enhancement of CP activation [50] 
Lipoproteins (Chylomicron, LDL, VLDL) Unknown [84] 
    
FHR-5 
C3b Inhibition of C3 convertase; weak cofactor activity [40] 
 Competition with FH [10] 
Heparin Unknown [40] 
CRP Unknown [40] 
Lipoproteins (HDL) Unknown [40] 
                                   HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein 408 
409 
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TABLE 2. CFHRs gene rearrangements associated with disease. 410 
411 
Disease Genetic findings Outcome Significance 
Risk/ 
Protection Prevalence References
aHUS 
CFH::CFHR1 hybrid 
genes 
Substitution of the C-terminal SCR of FH 
for that in FHR-1.  
Loss of complement regulation at 
cell surfaces. R 
Several unrelated 
cases described [28] 
CFHR1::CFH hybrid 
genes 
Substitution of the C-terminal SCR of 
FHR1 for that in FH.  
Two C-term SCRs for those of FH 
Loss of complement regulation at 
cell surfaces. R 
Few unrelated cases 
described [29, 85] 
CFH::CFHR3 hybrid 
gene 
Substitution of the last C-terminal SCR20 
of FH for the whole FHR-3.  
Loss of complement regulation at 
cell surfaces R Very rare [86] 
DelCFHR3-CFHR1 
DelCFHR1-CFHR4 
Loss of FHR-3 and FHR-1. 
Loss of FHR-1 and FHR-4.  
Associated with FH  autoantibodies 
impairing cell surface regulation.  R Common [12, 87, 88] 
C
3
G
 
DDD 
DupCFHR1 Mutant FHR-1 with SCR123412345 Abnormal oligomerization. Increased competition with FH. R Very rare [11] 
CFHR2::CFHR5 
hybrid gene 
Hybrid protein containing SCR1-2 of FHR-
2 followed by the whole FHR-5 molecule. 
Abnormal oligomerization. 
Increased competition with FH. R Very rare [14] 
C3-GN 
CFHR3::CFHR1 
hybrid gene 
Hybrid protein containing SCR1-2 of FHR-
3 followed by the whole FHR-1 molecule. 
Increased levels of FHR-1 
Increased competition with FH? R Very rare [19] 
CFHR5::CFHR2 
hybrid gene 
Hybrid protein containing SCR1-2 of FHR-
5 followed by the whole FHR-2 molecule. 
Increased levels of FHR-2 
Increased competition with FH? R Very rare [64] 
DupCFHR5 Mutant FHR-5 with SCR12123456789 Abnormal oligomerization. Increased competition with FH. R 
Several related cases 
described, 
1 unrelated 
[10, 15, 89] 
AMD 
 
DelCFHR3-CFHR1 
 
 
Loss of FHR-3 and FHR-1. 
 
 
No competition with FH? 
 
 
P 
 
 
Common 
 
[17] 
IgAN 
 
DelCFHR3-CFHR1 
 
 
Loss of FHR-3 and FHR-1. 
 
 
No competition with FH? 
 
 
P 
 
 
Common 
 
[16] 
SLE 
 
DelCFHR3-CFHR1 
 
Loss of FHR-3 and FHR-1.  No competition with FH? R Common [24] 
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Figure legends 627 
Figure 1. The FH/FHRs family of proteins 628 
A) Genomic organization of the CFH and CFHR1-5 genes. Arrows represent the genes with 629 
their names. The coloured boxes underneath indicate the sequence repeats. The vertical 630 
lines indicate the position of the exons of the CFH and CFHRs genes. 631 
B) Structural organization of the FH and FHR proteins. Short consensus repeats (SCRs) are 632 
represented by ovals and are numbered from the N-terminal end. Homologous SCRs are 633 
aligned. Colours illustrate SCRs presenting almost complete identity of amino acid 634 
sequences.  635 
C) Percentages of amino acid similarities are provided for SCRs 1 and 2 between FHR-1, 636 
FHR-2 and FHR-5 and for SCRs 6 and 7 in FH and SCRs 1 and 2 in FHR-3. The diagram 637 
also includes alignments to illustrate the similarities between the C-terminal regions of 638 
FH and the two FHR-1 alleles, as well as between FHR-3 and the two FHR-4 isoforms.  639 
D) FHR-1, FHR-2 and FHR-5 complexes for which there is experimental evidence. Models 640 
are drawn based on structural data demonstrating that the first two amino terminal SCRs 641 
of these proteins form dimers in a head to tail orientation [10]. For simplicity, tetramers 642 
are also depicted showing interactions through these SCRs. 643 
 644 
Figure 2. Main binding sites within FH for host and bacterial ligands. 645 
Figure depicts a diagram of the 20 SCR domains of FH. SCRs 1-4 are responsible for the 646 
cofactor and decay accelerating activities (yellow), and SCRs 7 and 19-20 contain major 647 
recognition sites for host and bacterial ligands (blue). The main host ligands are listed and 648 
their binding sites in FH indicated by red horizontal lines. Selected microbial ligands are 649 
similarly shown at the bottom part of the figure. 650 
 651 
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Figure 3. Competition between FH and FHRs on self, altered-self and pathogen surfaces. 652 
The figure depicts potential scenarios of FH/FHRs competition. Host cells, available data 653 
suggest that on normal endothelial cells, there is no competition between FH and FHR-1 and 654 
FHR-3. In aHUS, it has been established that the pathogenic mechanism is a defect in the 655 
protection of endothelial cells from complement damage. The prototypical genetic defects are 656 
C-terminal FH mutations and hybrid proteins involving FH, FHR1 and FHR3. The 657 
pathogenicity of the latter demonstrate both that FHR-1 and FHR-3 cannot replace the 658 
complement regulatory activities of FH and that they do not compete binding of FH to the 659 
aHUS relevant surfaces. Certain pathogens, like Neisseria express FH binding proteins in 660 
their surface that contribute to survival of the pathogen. Different FH/FHRs ratios could 661 
explain differences in susceptibility of the host to Neisseria infections. Alteration of the 662 
FH/FHRs ratio and modification of host surfaces by genetic or environmental factors, 663 
potentially contribute to sustain a competition between FH and the FHRs and result in 664 
pathology. Singular and altered host surfaces are terms used here in a wide and overlapping 665 
sense to refer, for example, to extracellular matrix and other cell surface components modified 666 
by aging, microbial and chemical agents, or by deposition of immune complexes (including 667 
those containing galactose deficient-IgA), or even to iC3b, C3dg opsonised surfaces. We like 668 
to suggest that on these singular and altered host surfaces an unbalanced FH/FHRs ratio 669 
causes complement dysregulation. 670 
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